Please login to the form below

Not currently logged in
Email:
Password:

Novo launches personalised diabetes management mobile app

Partners with Glooko on app that syncs blood glucose and activity data

Novo Nordisk

Novo Nordisk’s digital health deal with Glooko has yielded a new diabetes management app that the partners hope will enable users to better manage the condition.

The C4C app also includes relevant content and resources from Novo’s Cornerstones4Care personalised support programme.

David Moore, senior vice president of marketing at Novo Nordisk, said: “In today’s environment, in order to truly improve the prospects of the 29 million people with diabetes in the US, we must aspire towards leadership in digital health that complements our research and development expertise.

“That was the catalyst to our partnership with Glooko as well as IBM Watson Health and this milestone is just the beginning. Our companies share a common vision of empowering patients with ever improving digital health solutions,” he added.

The C4C app will initially enable people with diabetes to easily measure and track their blood glucose, activity and meals all in one place, and will sync a user’s blood glucose and activity data from the majority of currently available diabetes and exercise devices.

Rick Altiner, CEO of Glooko, said: “More people than ever are using mobile apps for chronic disease management and the apps, like the new C4C app, go beyond data capture or tracking to providing insights and recommendations based on that data.”

“Ultimately our digital health solution will help healthcare practitioners gain round-the-clock insight into heir patients, and empower people to better manage their diabetes.”

Article by
Gemma Jones

17th July 2017

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...
Waiting room
Immunotherapy combination trials Q&A
By Chris Learn and Martin Lachs...

Infographics